Last reviewed · How we verify

LDX Treatment

NYU Langone Health · FDA-approved active Small molecule

LDX Treatment is a Sympathomimetic amine; amphetamine prodrug Small molecule drug developed by NYU Langone Health. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Moderate to severe binge eating disorder. Also known as: Vyvanse.

LDX (lisdexamfetamine) is a prodrug that is metabolized to d-amphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system.

LDX (lisdexamfetamine) is a prodrug that is metabolized to d-amphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Moderate to severe binge eating disorder.

At a glance

Generic nameLDX Treatment
Also known asVyvanse
SponsorNYU Langone Health
Drug classSympathomimetic amine; amphetamine prodrug
TargetNorepinephrine transporter (NET); dopamine transporter (DAT)
ModalitySmall molecule
Therapeutic areaPsychiatry / Neurology
PhaseFDA-approved

Mechanism of action

LDX is an inactive compound that requires hepatic metabolism to release active d-amphetamine. Once converted, d-amphetamine acts as a sympathomimetic amine by stimulating the release of catecholamines (norepinephrine and dopamine) from nerve terminals and inhibiting their reuptake, leading to increased synaptic concentrations. This mechanism enhances attention, focus, and impulse control while reducing hyperactivity and impulsivity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LDX Treatment

What is LDX Treatment?

LDX Treatment is a Sympathomimetic amine; amphetamine prodrug drug developed by NYU Langone Health, indicated for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Moderate to severe binge eating disorder.

How does LDX Treatment work?

LDX (lisdexamfetamine) is a prodrug that is metabolized to d-amphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system.

What is LDX Treatment used for?

LDX Treatment is indicated for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Moderate to severe binge eating disorder.

Who makes LDX Treatment?

LDX Treatment is developed and marketed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).

Is LDX Treatment also known as anything else?

LDX Treatment is also known as Vyvanse.

What drug class is LDX Treatment in?

LDX Treatment belongs to the Sympathomimetic amine; amphetamine prodrug class. See all Sympathomimetic amine; amphetamine prodrug drugs at /class/sympathomimetic-amine-amphetamine-prodrug.

What development phase is LDX Treatment in?

LDX Treatment is FDA-approved (marketed).

What are the side effects of LDX Treatment?

Common side effects of LDX Treatment include Decreased appetite, Insomnia, Headache, Anxiety, Dry mouth, Abdominal pain.

What does LDX Treatment target?

LDX Treatment targets Norepinephrine transporter (NET); dopamine transporter (DAT) and is a Sympathomimetic amine; amphetamine prodrug.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing